share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  2024/06/28 04:39

Moomoo AI 已提取核心訊息

Illumina, Inc., a leading biotechnology company, has successfully completed the spin-off of its subsidiary GRAIL, Inc. on June 24, 2024. The separation was executed as a tax-free distribution of 26.5 million shares of GRAIL common stock to Illumina shareholders, with Illumina retaining a 14.5% ownership stake in GRAIL. The spin-off resulted in GRAIL becoming an independent public company, trading under the symbol 'GRAL' on the NASDAQ Global Select Market as of June 25, 2024. To facilitate the spin-off, Illumina provided GRAIL with $974 million in Disposal Funding, less GRAIL's cash on hand at the time of the spin-off. To fund this, Illumina entered into a credit agreement for a $750 million term loan with a variable interest rate, which was fully drawn...Show More
Illumina, Inc., a leading biotechnology company, has successfully completed the spin-off of its subsidiary GRAIL, Inc. on June 24, 2024. The separation was executed as a tax-free distribution of 26.5 million shares of GRAIL common stock to Illumina shareholders, with Illumina retaining a 14.5% ownership stake in GRAIL. The spin-off resulted in GRAIL becoming an independent public company, trading under the symbol 'GRAL' on the NASDAQ Global Select Market as of June 25, 2024. To facilitate the spin-off, Illumina provided GRAIL with $974 million in Disposal Funding, less GRAIL's cash on hand at the time of the spin-off. To fund this, Illumina entered into a credit agreement for a $750 million term loan with a variable interest rate, which was fully drawn on June 20, 2024. The pro forma financial statements reflect the financial position and results of operations as if the spin-off had occurred at the beginning of the periods presented. The pro forma balance sheet shows a reduction in assets and liabilities due to the spin-off, and the pro forma statements of operations reflect the removal of GRAIL's financial results from Illumina's post-spin-off.
領先的生物技術公司Illumina, Inc.於2024年6月24日成功完成了其子公司GRAIL, Inc.的分拆。該分離被執行爲向Illumina股東發行了2650萬股GRAIL普通股的無稅分配,Illumina仍然保留GRAIL14.5%的所有權。分拆導致GRAIL成爲獨立的上市公司,在2024年6月25日開始在納斯達克全球精選市場上交易,股票代碼爲“GRAL”。爲方便這次分拆,Illumina向GRAIL提供了9.74億美元的處置資金,減去分拆時GRAIL手中的現金。爲了籌集這筆資金,Illumina與一個可變利率的信貸協議簽訂了7.5億美元的借款期限貸款,該貸款於2024年6月20日已全部兌現。經過剝離後的基本報表反映了在提出期初時進行分拆的財務狀況和業務結果。經過剝離後的資產負債表顯示資產和負債的減少,經過剝離後的業務結果表反映了從Illumina發帖開始除GRAIL財務結果。
領先的生物技術公司Illumina, Inc.於2024年6月24日成功完成了其子公司GRAIL, Inc.的分拆。該分離被執行爲向Illumina股東發行了2650萬股GRAIL普通股的無稅分配,Illumina仍然保留GRAIL14.5%的所有權。分拆導致GRAIL成爲獨立的上市公司,在2024年6月25日開始在納斯達克全球精選市場上交易,股票代碼爲“GRAL”。爲方便這次分拆,Illumina向GRAIL提供了9.74億美元的處置資金,減去分拆時GRAIL手中的現金。爲了籌集這筆資金,Illumina與一個可變利率的信貸協議簽訂了7.5億美元的借款期限貸款,該貸款於2024年6月20日已全部兌現。經過剝離後的基本報表反映了在提出期初時進行分拆的財務狀況和業務結果。經過剝離後的資產負債表顯示資產和負債的減少,經過剝離後的業務結果表反映了從Illumina發帖開始除GRAIL財務結果。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息